A rescue inhaler, also known as asthma inhaler, is a handheld medical device used to quickly relieve symptoms of asthma by delivering medications like albuterol to the lungs. Asthma inhalers contain medications like albuterol, salbutamol, terbutaline and others that relax the airway muscles and prevent bronchospasms during asthma attacks. The inhaler generally use a propellant like CFC or HFC to spray a fine mist containing the medication into the mouth so it can be inhaled into the lungs. The global rescue inhaler market is estimated to be valued at US$ 15.5 Bn in 2023 and is expected to exhibit a CAGR of 8.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
The global rescue inhaler market growth is primarily driven by the rising prevalence of asthma around the world. According to WHO, around 339 million people suffer from asthma globally and is one of the common non-communicable diseases. Additionally, increasing pollution levels, growing exposure to allergens and changing climate are some of the factors leading to surge in asthma patient pool. Furthermore, new product launches, increasing R&D investments by players, and technological advancements in rescue inhalers resulting in portable and easy-to-use devices will further aid the market growth over the forecast period. For instance, the drug delivery devices use metered dose inhaler (MDI) technology that releases exact medication dosage to improve medication adherence. Moreover, growing health awareness and availability of affordable treatment options in developing regions will expand the market during 2023-2030.

SWOT Analysis
Strength: Rescue inhalers such as albuterol provide quick relief for asthma sufferers and offer peace of mind for mild asthma attacks. Many people are familiar with rescue inhalers and find them easy to use correctly with practice. They come pre-measured and require no mixing or complex preparation, allowing for quick administration.

Weakness: Over-reliance on rescue inhalers alone can worsen asthma over time without the use of preventative medications. Frequent use may also signal the need to better control underlying asthma. The effects of rescue inhalers are temporary and do not treat the underlying inflammation driving asthma symptoms.

Opportunity: New rescue inhaler formulations and delivery methods could drive patient preference and compliance. Combination rescue/controller therapies could simplify treatment regimens. Expanding access in developing countries represents a growth opportunity.

Threats: Increased scrutiny of overprescribing and overuse could dampen market growth. Generic competition for established products poses pricing pressures. Side effects or safety concerns could damage brand reputation.

Key Takeaways
The global rescue inhaler market is expected to witness high growth over the forecast period of 2023 to 2030. The market size is projected to reach US$ 15.5 billion by 2024, growing at an estimated CAGR of 8.8% through 2030.

Regional analysis reveals North America currently dominates the market due to high asthma prevalence and Medical reimbursement policies. However, Asia Pacific is poised to emerge as the fastest growing regional market owing to rising awareness, improved diagnosis rates, and economic growth expanding access to healthcare.

Key players operating in the rescue inhaler market include GSK, Merck, Boehringer Ingelheim, Teva, and Novartis. GSK holds the leading market share with its widely used Airomir and Ventolin brands. Other major players are focused on developing quick-acting drug-device combination therapies and expanding into high growth emerging markets through partnerships with local companies.